Stocktoria
QHSLab, Inc. USAQ
QHSLab, Inc. (USAQ) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $2.7M at a -17.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.2 |
| Retained earnings / assets | -1.798 |
| EBIT / assets | 0.06 |
| Equity / liabilities | 2.976 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| USAQ | QHSLab, Inc. | 4/9 | -1.02 | — | — |
| OSRH | OSR Health, Inc. | — | 1.04 | — | — |
| FEMY | FEMASYS INC | 2/9 | — | — | — |
| AURX | Nuo Therapeutics, Inc. | 3/9 | — | — | — |
| EBRCZ | EBR Systems, Inc. | 2/9 | -12.31 | — | — |
| TNON | Tenon Medical, Inc. | 5/9 | — | — | — |
| EMED | Electromedical Technologies, Inc | 4/9 | — | — | — |
About QHSLab, Inc.
QHSLab, Inc., a medical device technology and software-as-a-service (SaaS) company, provides tools to evaluate and treat chronic disease and preventive care through reimbursable procedures. The company focuses on value-based healthcare, informatics, and algorithmic personalized medicine, including digital therapeutics, behavior based remote patient monitoring, and chronic care and preventive medicine. Its digital healthcare and clinical decision support and point of care solutions also support non face to face remote patient and therapeutic monitoring, address chronic care, and preventive medicine. The company provides quality health system lab expert system (QHSLab), designed to function as an extension of a medical practice's existing clinical workflow that supports structured screening, automated documentation, and digital follow-up while minimizing disruption to physicians and staff; and AllergiEnd, a diagnostic and allergen immunotherapy system for the busy non-allergist in a primary care setting. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as USA Equities Corp. and changed its name to QHSLab, Inc. in April 2022. The company was incorporated in 1983 and is based in West Palm Beach, Florida.
FAQ
Is USAQ financially healthy?
QHSLab, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does USAQ pay a dividend?
No, QHSLab, Inc. does not currently pay a dividend.
How profitable is USAQ?
In FY2025, QHSLab, Inc. had a net margin of -17.0% and a return on equity of -28.1%.
Is USAQ a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on QHSLab, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.